Working… Menu

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02415413
Recruitment Status : Active, not recruiting
First Posted : April 14, 2015
Last Update Posted : February 17, 2021
Celgene Corporation
Information provided by (Responsible Party):
PETHEMA Foundation

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : July 5, 2018
Estimated Study Completion Date : June 2027